Carbetocin
As of the edition of 20 October 2026, Carbetocin is a protein: marketed, first approved in 2006 (FR); acts on OXTR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Protein
- Brand name
- Pabal
- First approved
- 6 July 2006 (FR)
- Approvals on record
- 7 in 6 regions
- Holder of the most recent approval
- LABORATÓRIOS FERRING LTDA; 4 holders in all
- Registered trials
- 48, 1 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Cancer; Nutrition and metabolism; Skin and connective tissue; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OXTR | Oxytocin receptor | P30559 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 11 | 2 | 0 |
| Phase 1 | 4 | 2 | 1 | 0 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 5 | 2 | 1 | 1 |
| Phase 4 | 21 | 14 | 3 | 0 |
| All trials | 48 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ferring Pharmaceuticals | Originator and Lead sponsor of trials | 2007 to now |